Table 3.
Risk Estimate (95% CI) [number of studies] |
|||
---|---|---|---|
Cancer Site | Incidence |
Mortality |
Incidence and Mortality |
Cancer sites with no statistically significant associations | |||
Oral and Pharyngeal | |||
Good Studies only | 0.80 (0.50 – 1.28) [2] | 1.07 (0.70 – 1.63) [6] | 0.96 (0.68 – 1.34) [8] |
Good and Adequate | 0.80 (0.50 – 1.28) [2] | 1.08 (0.75 – 1.56) [7] | 0.95 (0.70 – 1.30) [9] |
All Studies | 0.80 (0.50 – 1.28) [2] | 1.04 (0.84 – 1.30) [11] | 0.94 (0.77 – 1.15) [13] |
Laryngeal | |||
Good Studies only | 0.77 (0.50 – 1.18) [2] | 0.68 (0.36 – 1.30) [4] | 0.74 (0.52 – 1.06) [6] |
Good and Adequate | 0.77 (0.50 – 1.18) [2] | 0.68 (0.36 – 1.30) [4] | 0.74 (0.52 – 1.06) [6] |
All Studies | 1.21 (0.53 – 2.76) [3] | 0.94 (0.67 – 1.31) [8] | 1.02 (0.74 – 1.41) [11] |
Lung | |||
Good Studies only | 0.78 (0.52 – 1.18) [7] | 0.96 (0.82 – 1.11) [9] | 0.88 (0.74 – 1.05) [14] |
Good and Adequate | 0.85 (0.66 – 1.09) [10] | 0.98 (0.85 – 1.13) [10] | 0.92 (0.81 – 1.05) [18] |
All Studies | 0.85 (0.66 – 1.09) [10] | 0.99 (0.90 – 1.09) [17] | 0.95 (0.86 – 1.04) [25] |
Esophageal | |||
Good Studies only | 0.89 (0.49 – 1.62) [3] | 0.90 (0.47 – 1.71) [5] | 0.93 (0.60 – 1.43) [8] |
Good and Adequate | 1.09 (0.75 – 1.58) [5] | 0.90 (0.47 – 1.71) [5] | 1.02 (0.74 – 1.40) [10] |
All Studies | 1.09 (0.75 – 1.58) [5] | 1.02 (0.80 – 1.31) [10] | 1.06 (0.87 – 1.29) [15] |
Stomach | |||
Good Studies only | 0.87 (0.45 – 1.70) [5] | 1.03 (0.85 – 1.24) [10] | 0.99 (0.80 – 1.25) [13] |
Good and Adequate | 0.87 (0.60 – 1.26) [7] | 1.03 (0.85 – 1.24) [10] | 0.96 (0.80 – 1.16) [15] |
All Studies | 0.87 (0.60 – 1.26) [7] | 1.05 (0.91 – 1.21) [17] | 0.98 (0.84 – 1.13) [22] |
Liver and Gallbladder | |||
Good Studies only | 0.77 (0.41 – 1.45) [2] | 1.10 (0.80 – 1.53) [7] | 1.02 (0.77 – 1.37) [8] |
Good and Adequate | 0.91 (0.56 – 1.47) [3] | 1.10 (0.80 – 1.53) [7] | 1.04 (0.79 – 1.36) [9] |
All Studies | 0.91 (0.56 – 1.47) [3] | 1.14 (0.94 – 1.38) [13] | 1.11 (0.93 – 1.32) [15] |
Lymphatic and Hematopoietic | |||
Good Studies only | 0.32 (0.08 – 1.25) [1] | 0.92 (0.67 – 1.26) [7] | 0.85 (0.61 – 1.20) [7] |
Good and Adequate | 0.32 (0.08 – 1.25) [1] | 0.84 (0.62 – 1.14) [8] | 0.80 (0.59 – 1.10) [8] |
All Studies | 0.32 (0.08 – 1.25) [1] | 1.11 (0.91 – 1.35) [13] | 1.07 (0.87 – 1.32) [13] |
Urinary | |||
Good Studies only | 1.02 (0.33 – 3.12) [1] | 0.60 (0.23 – 1.55) [2] | 0.67 (0.34 – 1.35) [3] |
Good and Adequate | 1.02 (0.33 – 3.12) [1] | 0.85 (0.47 – 1.56) [4] | 0.86 (0.53 – 1.34) [5] |
All Studies | 1.02 (0.33 – 3.12) [1] | 1.12 (0.59 – 2.12) [5] | 1.10 (0.63 – 1.91) [6] |
Skin cancer * | |||
Good Studies only | 0.98 (0.60 – 1.59) [3] | 1.08 (0.78 – 1.50) [4] | 1.04 (0.82 – 1.31) [7] |
Good and Adequate | 0.98 (0.60 – 1.59) [3] | 1.08 (0.78 – 1.50) [4] | 1.04 (0.82 – 1.31) [7] |
All Studies | 0.98 (0.60 – 1.59) [3] | 1.34 (0.98 – 1.83) [8] | 1.18 (0.92 – 1.52) [11] |
*, Includes Melanoma and Non-melanoma skin cancer.